Review




Structured Review

Novartis p-selectin antagonist
Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD
P Selectin Antagonist, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-selectin+antagonist/p+selectin+inhibitor/pmc10727073-26-0-5
Average 90 stars, based on 1 article reviews
p-selectin antagonist - by Bioz Stars, 2026-09
90/100 stars

Images

1) Product Images from "Using disease-modifying therapies in sickle cell disease"

Article Title: Using disease-modifying therapies in sickle cell disease

Journal: Hematology: the American Society of Hematology Education Program

doi: 10.1182/hematology.2023000485

Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD
Figure Legend Snippet: Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD

Techniques Used: Clinical Proteomics, Drug discovery, In Vitro, Biomarker Discovery, Saline, Control, Activity Assay, Concentration Assay

Related Articles

Clinical Proteomics:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Drug discovery:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

In Vitro:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Biomarker Discovery:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Saline:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Control:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Activity Assay:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Concentration Assay:

Article Title: Using disease-modifying therapies in sickle cell disease
Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.



Similar Products

94
MedChemExpress molecule p selectin antagonist
Molecule P Selectin Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-selectin+antagonist/PSI-697/pm40025016-316-1-6
Average 94 stars, based on 1 article reviews
molecule p selectin antagonist - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
Novartis p-selectin antagonist
Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD
P Selectin Antagonist, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-selectin+antagonist/p+selectin+inhibitor/pmc10727073-26-0-5
Average 90 stars, based on 1 article reviews
p-selectin antagonist - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

93
R&D Systems p selectin antagonist
Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD
P Selectin Antagonist, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-selectin+antagonist/Human+P-Selectin%2FCD62P+Antibody/pm36781864-364-8-13
Average 93 stars, based on 1 article reviews
p selectin antagonist - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

90
Revotar Biopharmaceuticals AG non-carbohydrate p-selectin antagonists mimicking slex
Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD
Non Carbohydrate P Selectin Antagonists Mimicking Slex, supplied by Revotar Biopharmaceuticals AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-selectin+antagonist/non+carbohydrate+p+selectin+antagonists+mimicking+slex/10__1039_slash_D2CS00954D-862-19-9
Average 90 stars, based on 1 article reviews
non-carbohydrate p-selectin antagonists mimicking slex - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Glycomimetics inc glycomimetic antagonists for both e- and p-selectins
Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD
Glycomimetic Antagonists For Both E And P Selectins, supplied by Glycomimetics inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/p-selectin+antagonist/glycomimetic+antagonists+for+both+e++and+p+selectins/us11291407-1169-21-140
Average 90 stars, based on 1 article reviews
glycomimetic antagonists for both e- and p-selectins - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

Image Search Results


Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD

Journal: Hematology: the American Society of Hematology Education Program

Article Title: Using disease-modifying therapies in sickle cell disease

doi: 10.1182/hematology.2023000485

Figure Lengend Snippet: Actively recruiting clinical trials of antioxidants, antiadhesive, and anti-inflammatory agents in SCD

Article Snippet: P-selectin antagonist , Crizanlizumab , Novartis Pharmaceuticals , NCT03938454 (SPARTAN) , Phase 2 , IV infusion every 2 wk for first month and then every 4 wk × 51 wk , 56/ ≥ 16 y , Evaluate efficacy in priapism, uncomplicated VOC events.

Techniques: Clinical Proteomics, Drug discovery, In Vitro, Biomarker Discovery, Saline, Control, Activity Assay, Concentration Assay